Administration of mesenchymal stem cells (MSCs) to diseased hearts improves cardiac
function and reduces scar. These effects occur via stimulation of endogenous repair …

Mesenchymal stem cells (MSCs) are broadly distributed cells that retain postnatal capacity
for self-renewal and multilineage differentiation. MSCs evade immune detection, secrete an …

Since both myocardium and vasculature in the heart are excessively damaged following
myocardial infarction (MI), therapeutic strategies for treating MI hearts should concurrently …

Cardiovascular disease is a leading cause of mortality in the world and is exacerbated by
the presence of cardiac fibrosis, defined by the accumulation of noncontractile extracellular …

Despite the success of current therapies for acute myocardial infarction (MI), many patients
still develop adverse cardiac remodeling and heart failure. With the growing prevalence of …

Mesenchymal stem cells have been used for cardiovascular regenerative therapy for
decades. These cells have been established as one of the potential therapeutic agents …

Cardiovascular disease is the leading cause of death worldwide. Reperfusion therapy is
vital to patient survival after a heart attack but can cause myocardial ischemia/reperfusion …

Introduction Ischemic heart diseases, especially the myocardial infarction, is a major hazard
problem to human health. Despite substantial advances in control of risk factors and …

Cardiac ageing manifests as a decline in function leading to heart failure. At the cellular
level, ageing entails decreased replicative capacity and dysregulation of cellular processes …

As part of the TACTICS (Transnational Alliance for Regenerative Therapies in
Cardiovascular Syndromes) series to enhance regenerative medicine, here, we discuss the …